HIGH-GRADE SEROUS PRIMARY PERITONEAL CANCER
Clinical trials for HIGH-GRADE SEROUS PRIMARY PERITONEAL CANCER explained in plain language.
Never miss a new study
Get alerted when new HIGH-GRADE SEROUS PRIMARY PERITONEAL CANCER trials appear
Sign up with your email to follow new studies for HIGH-GRADE SEROUS PRIMARY PERITONEAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for drug-resistant ovarian cancer: experimental pill targets tumor weakness
Disease control Recruiting nowThis study tests an experimental drug called azenosertib (ZN-c3) in people with a specific type of ovarian, fallopian tube, or peritoneal cancer that no longer responds to platinum chemotherapy. The drug aims to shrink or control tumors by blocking a protein that cancer cells nee…
Matched conditions: HIGH-GRADE SEROUS PRIMARY PERITONEAL CANCER
Phase: PHASE2 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for ovarian cancer: phase 3 trial tests targeted drug against Tough-to-Treat tumors
Disease control Recruiting nowThis large Phase 3 study tests a new medicine called Sofetabart Mipitecan for people with ovarian, fallopian tube, or peritoneal cancer. It includes two groups: those whose cancer stopped responding to platinum chemotherapy within six months (platinum-resistant), and those whose …
Matched conditions: HIGH-GRADE SEROUS PRIMARY PERITONEAL CANCER
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radioactive 'Bullets' aim to stop ovarian cancer spread in new trial
Disease control Recruiting nowThis study tests a single injection of Radspherin®, a radioactive treatment given directly into the abdomen, for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has spread to the lining of the belly. About 114 participants will receive either stand…
Matched conditions: HIGH-GRADE SEROUS PRIMARY PERITONEAL CANCER
Phase: PHASE2 • Sponsor: Oncoinvent Solutions AS • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Cancer-Killing virus takes on ovarian cancer in first human trial
Disease control Recruiting nowThis early-stage trial tests a new treatment called THEO-260, a virus designed to infect and destroy cancer cells. It is given directly into the abdomen to 18 people with advanced ovarian cancer that no longer responds to platinum chemotherapy. The main goals are to find a safe d…
Matched conditions: HIGH-GRADE SEROUS PRIMARY PERITONEAL CANCER
Phase: PHASE1 • Sponsor: Theolytics Limited • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Virus therapy takes on hard-to-treat ovarian cancer
Disease control Recruiting nowThis study tests a new treatment called THEO-260, a virus designed to attack cancer cells, in people with advanced ovarian cancer that no longer responds to platinum chemotherapy. About 44 participants will receive different doses of the virus through an IV to find a safe dose an…
Matched conditions: HIGH-GRADE SEROUS PRIMARY PERITONEAL CANCER
Phase: PHASE1, PHASE2 • Sponsor: Theolytics Limited • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Ovarian cancer clues hidden in blood and tissue
Knowledge-focused Recruiting nowThis study collects blood, tumor tissue, and other fluids from people with advanced ovarian cancer to find biological markers (biomarkers). Researchers will analyze these samples to understand why some patients live longer or respond better to treatment. Results may be shared wit…
Matched conditions: HIGH-GRADE SEROUS PRIMARY PERITONEAL CANCER
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC